Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes (original) (raw)

Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study

The American Journal of Medicine, 2015

Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Jeffrey Kopp

Journal of Clinical Medicine

View PDFchevron_right

Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?

Frédéric Lioté

Arthritis & Rheumatism, 2007

View PDFchevron_right

Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression

Yi-jen Fang

Mediators of Inflammation

View PDFchevron_right

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

Dott/Prof. Raffaele Ivan Cincione

Medical Principles and Practice, 2020

View PDFchevron_right

Evaluation of Allopurinol (Xanthine Oxidase Inhibitor) inManagement of Primary Gout (Niqras)

Mohammad Saad Ahmad Khan

2020

View PDFchevron_right

Combination urate-lowering therapy in the treatment of gout: What is the evidence?

Fernando Perez-ruiz

Seminars in Arthritis and Rheumatism, 2018

View PDFchevron_right

Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia

Irada Khalilova

Rheumatology, 2014

View PDFchevron_right

Efficacy and safety of febuxostat in patients with hyperuricemia and gout

Luis Espinoza

Therapeutic Advances in Musculoskeletal Disease, 2011

View PDFchevron_right

Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use*

Richard A Brook

Current Medical Research and Opinion, 2007

View PDFchevron_right

Therapeutic approaches to chronic hyperuricemia and gout

Roberto Pontremoli

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2014

View PDFchevron_right

Diet may be the most relevant feature for the success of urate lowering therapy in gout

Bilge Kalkan

Acta Facultatis Medicae Naissensis, 2020

View PDFchevron_right

Gout Study Group: Update on hyperuricemia and gout

Fernando Perez-ruiz

Joint Bone Spine, 2009

View PDFchevron_right

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment

Aleš Kvasnička

2023

View PDFchevron_right

Uric Acid Lowering Effect of Xanthine Oxidase Inhibitors, Febuxostat and Allopurinol in an Animal Model

MAHREEN AKHTAR

2018

View PDFchevron_right

Renal excretion of hypoxanthine and xanthine in primary gout

Juan Garcia Puig

The American Journal of Medicine, 1988

View PDFchevron_right

Gout and Hyperuricemia—Serious Risk Factors for Morbidity and Mortality or Just Indicators of “The Good Life”—The Evidence to Date

Joseph Markenson

Current Treatment Options in Rheumatology, 2015

View PDFchevron_right

Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout

şervan özalkak

JCR: Journal of Clinical Rheumatology, 2017

View PDFchevron_right

A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesis

Fernando Perez-ruiz

Arthritis & Rheumatism, 2011

View PDFchevron_right

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level

Peter Chapman

Clinical pharmacology and therapeutics, 2011

View PDFchevron_right

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients

Lian-Chin Wang

Arthritis Research & Therapy

View PDFchevron_right

Biostatistical Analysis and Possible Forecasting of Relationship Between Uric Acid and Specific Laboratory Tests in Cases of Gouty Arthritis

Mirela Nicolov

Revista de Chimie

View PDFchevron_right

Comparative Study between Febuxostat and Allupurinol based on Safety and Urate-Lowering Efficacy in Gout Patients of Indian Population

Shalini Rawat

International Journal of Current Microbiology and Applied Sciences, 2016

View PDFchevron_right

Pharmacological overview for therapy of gout and hyperuricemia

Madhura Bhosale

International journal of health sciences

View PDFchevron_right

Update on the management of hyperuricemia and gout

Robert Keenan

Bulletin of the NYU hospital for joint diseases

View PDFchevron_right

Clinical and epidemiological aspects of gout, a dysmetabolic disabling disorder

luana macovei

Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i

View PDFchevron_right

Gout: A clinical overview and its association with cardiovascular diseases

Matthijs Janssen

View PDFchevron_right

Serum Uric Acid publication

Gunjan Mishra

International Journal of Sciences, 2014

View PDFchevron_right

Physicochemical features and structural analysis of xanthine oxidase as a potential therapeutic target to prevent gout

Sara Zahid

Journal of Radiation Research and Applied Sciences

View PDFchevron_right

Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes (original) (raw)

Related papers